Regenxbio Return on Equity (ROE) Growth & History (RGNX)

Regenxbio's return on equity was −107.00% for fiscal 2025.

View full Regenxbio company overview

Regenxbio annual return on equity history

Regenxbio annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20252025-12-31−107.00%−27.51 pp
20242024-12-31−79.49%−15.84 pp
20232023-12-31−63.65%−19.87 pp
20222022-12-31−43.78%−66.17 pp
20212021-12-3122.39%+49.26 pp
20202020-12-31−26.87%−7.12 pp
20192019-12-31−19.76%−48.64 pp
20182018-12-3128.89%+71.33 pp
20172017-12-31−42.45%−9.18 pp
20162016-12-31−33.27%−10.29 pp
20152015-12-31−22.98%

Regenxbio return on equity trends

Over the last five fiscal years, Regenxbio's return on equity decreased from −26.87% to −107.00%, a change of −80.13 percentage points. The latest reported quarter, Q2 2026, shows 48.92%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Regenxbio source filings ↗

Community posts

It’s quiet here.

No posts about RGNX yet. Start the conversation.

Write the first post